OTCMKTS:PVCTProvectus Biopharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Provectus Biopharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.05 +0.00 (+5.38 %) (As of 06/1/2020 04:00 PM ET) Add Compare Share Today's Range$0.04Now: $0.05▼$0.0550-Day Range$0.04MA: $0.05▼$0.0552-Week Range$0.03Now: $0.05▼$0.08Volume277,397 shsAverage Volume301,394 shsMarket Capitalization$18.36 millionP/E RatioN/ADividend YieldN/ABeta0.4 ProfileAdvanced ChartCompetitorsEarningsFinancialsInsider TradesHeadlinesSEC FilingsSocial Media Provectus Biopharmaceuticals, Inc., a biopharmaceutical company, engages in developing drugs based on halogenated xanthenes for oncology and dermatology indications. Its prescription drug candidates include PV-10, which is in Phase III study for cutaneous melanoma; completed Phase II study for metastatic melanoma; completed Phase I study for liver and breast cancers; and phase 1b/2 study for pembrolizumab. The company is also developing PH-10 that has completed Phase II randomized study for the treatment of psoriasis and atopic dermatitis. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Provectus Biopharmaceuticals. Previous Next 3.0 Community Rank Outperform VotesProvectus Biopharmaceuticals has received 84 “outperform” votes. (Add your “outperform” vote.)Underperform VotesProvectus Biopharmaceuticals has received 56 “underperform” votes. (Add your “underperform” vote.)Community SentimentProvectus Biopharmaceuticals has received 60.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Provectus Biopharmaceuticals and other stocks. Vote “Outperform” if you believe PVCT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PVCT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldProvectus Biopharmaceuticals does not currently pay a dividend.Dividend GrowthProvectus Biopharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Provectus Biopharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.30% of the stock of Provectus Biopharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 0.03% of the stock of Provectus Biopharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.60 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:PVCT Previous SymbolNYSEMKT:PVCT CUSIPN/A CIK315545 Webwww.provectusbio.com Phone866-594-5999Debt Debt-to-Equity RatioN/A Current Ratio0.13 Quick Ratio0.13Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.06) per share Price / Book-0.78Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-6,920,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-448.70%Miscellaneous Employees2 Outstanding Shares390,689,000Market Cap$18.36 million Next Earnings Date8/13/2020 (Estimated) OptionableNot Optionable OTC:PVCT Rates by TradingView Receive PVCT News and Ratings via Email Sign-up to receive the latest news and ratings for PVCT and its competitors with MarketBeat's FREE daily newsletter. Provectus Biopharmaceuticals (OTCMKTS:PVCT) Frequently Asked Questions How has Provectus Biopharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Provectus Biopharmaceuticals' stock was trading at $0.0445 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PVCT stock has increased by 5.6% and is now trading at $0.0470. View which stocks have been most impacted by Coronavirus. When is Provectus Biopharmaceuticals' next earnings date? Provectus Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Provectus Biopharmaceuticals. Has Provectus Biopharmaceuticals been receiving favorable news coverage? Press coverage about PVCT stock has been trending very positive recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Provectus Biopharmaceuticals earned a daily sentiment score of 3.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutProvectus Biopharmaceuticals. Who are some of Provectus Biopharmaceuticals' key competitors? Some companies that are related to Provectus Biopharmaceuticals include Moleculin Biotech (MBRX), Stealth BioTherapeutics (MITO), Proteostasis Therapeutics (PTI), CannTrust (CNTTF), Capricor Therapeutics (CAPR), DiaMedica Therapeutics (DMAC), VERONA PHARMA P/S (VRNA), Elite Pharmaceuticals (ELTP), Vaccinex (VCNX), Evoke Pharma (EVOK), Iterum Therapeutics (ITRM), Aridis Pharmaceuticals (ARDS), Diffusion Pharmaceuticals (DFFN), Aclaris Therapeutics (ACRS) and American Brivision (Holding) (ABVC). View all competitors. What other stocks do shareholders of Provectus Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Provectus Biopharmaceuticals investors own include Vertex Energy (VTNR), Good Times Restaurants (GTIM), Merck & Co., Inc. (MRK), Oncolytics Biotech (ONC), Cytori Therapeutics (CYTX), DARA Biosciences (DARA), Energy Transfer LP Unit (ET), Gilead Sciences (GILD), iShares Nasdaq Biotechnology ETF (IBB) and MaxLinear (MXL). Who are Provectus Biopharmaceuticals' key executives? Provectus Biopharmaceuticals' management team includes the following people: Dr. Timothy C. Scott, Pres (Age 61)Dr. Eric A. Wachter, Co-Founder & Chief Technology Officer (Age 56)Mr. Bruce Horowitz, Chief Operations Consultant & Director (Age 63)Ms. Heather Raines, Chief Financial Officer (Age 52) What is Provectus Biopharmaceuticals' stock symbol? Provectus Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "PVCT." How do I buy shares of Provectus Biopharmaceuticals? Shares of PVCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Provectus Biopharmaceuticals' stock price today? One share of PVCT stock can currently be purchased for approximately $0.05. How big of a company is Provectus Biopharmaceuticals? Provectus Biopharmaceuticals has a market capitalization of $18.36 million. Provectus Biopharmaceuticals employs 2 workers across the globe. What is Provectus Biopharmaceuticals' official website? The official website for Provectus Biopharmaceuticals is www.provectusbio.com. How can I contact Provectus Biopharmaceuticals? Provectus Biopharmaceuticals' mailing address is 10025 INVESTMENT DRIVE SUITE 250, KNOXVILLE TN, 37932. The company can be reached via phone at 866-594-5999 or via email at [email protected] This page was last updated on 6/2/2020 by MarketBeat.com Staff
